The primary objective of this systematic review is to determine whether the detection of ctDNA in blood liquid biopsy during the neoadjuvant or adjuvant treatment setting is associated with survival outcomes (including recurrence-free survival and overall survival) in patients with HR+/HER2− stages I–III breast cancer. The gene discussed is HR; the disease is breast carcinoma.